Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Tumor & fibroid embolization · Massachusetts | Tumor & fibroid embolization · New York | |
|---|---|---|
| Surgeons, 2024 | 12 | 22 |
| Medicare fee-for-service cases | 677 | 1,661 |
| Growth since 2019 (Medicare FFS) | +16%/yr | +10%/yr |
| Forecast cases (Medicare FFS) | 1,170 in 2030 | 3,360 in 2030 |
| Forecast growth | +9.5%/yr to 2030 | +12%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 0.7 | 0.9 |
| Medicare Advantage share | 39% | 57% |
| Out of hospital | 46% (+46 pts since 2019) | 48% (+40 pts since 2019) |
| Cases per surgeon | 56 | 76 |
| Top 10 surgeons' share | 95% | 79% |
| Surgeons growing | 1 | 4 |
| New since the base year | 2 | 6 |
| Likely to stop billing it | 4 by 2026 | 2 by 2026 |
| Forecast miss, 1 year (procedure) | 11% | 11% |
| Company payments per surgeon | $40K | $62K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.